Sylvie M. Guichard
0000-0003-1143-2805
Publication & Citation Trends
Publications
0 total
FT-4202, a selective pyruvate kinase R activator for sickle cell disease. OA
Cited by 3
Semantic Scholar
FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer OA
Cited by 26
Semantic Scholar
Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease OA
Cited by 30
Semantic Scholar
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.
Cited by 90
Semantic Scholar
Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia OA
Cited by 5
Semantic Scholar
The Courage study: A first-in-human phase 1 study of the CBP/p300 inhibitor FT-7051 in men with metastatic castration-resistant prostate cancer.
Cited by 7
Semantic Scholar
FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice. OA
Cited by 21
Semantic Scholar
Ex-Vivo FT-4202 Treatment Improves Hemoglobin Oxygen Affinity and Membrane Health in Red Blood Cells of Patients with Hemoglobin SS and Hemoglobin SC Disease Irrespective of Prior Hydroxyurea Use
Cited by 1
Semantic Scholar
Research Topics
PI3K/AKT/mTOR signaling in cancer
(57)
Gastrointestinal Tumor Research and Treatment
(29)
Platelet Disorders and Treatments
(25)
Cancer therapeutics and mechanisms
(25)
FOXO transcription factor regulation
(19)
Affiliations
AstraZeneca (United Kingdom)
Cincinnati Children's Hospital Medical Center
Academy of Medical Sciences
St. Jude Children's Research Hospital
DuPont (United States)